Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat DDI study with Ethinyl Estradiol and Levonorgestrel
NCT06657105Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of baxdrostat in hypertension (HTN), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time zero to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 1 more. Started Nov 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06657105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657105.